 Oncternal Therapeutics, Inc. Nasdaq: ONCT, a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will host a call with a key opinion leader KOL and members of the Oncternal management team to discuss the current treatment landscape of mantle cell lymphoma MCL and updates on the use of cirmtuzumab to treat patients with MCL on Wednesday, July 29, 2020 at 1:30 p.m. Eastern Time. 